Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection London, UK, 22 May 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round. The additional investment […]